1
|
Ochiai T, Nagayama T, Matsui K, Amano K, Sano T, Wakabayashi T, Iwatsubo T. Tauroursodeoxycholic Acid Attenuates Diet-Induced and Age-Related Peripheral Endoplasmic Reticulum Stress and Cerebral Amyloid Pathology in a Mouse Model of Alzheimer's Disease. J Prev Alzheimers Dis 2021; 8:483-494. [PMID: 34585224 DOI: 10.14283/jpad.2021.33] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Obesity and diabetes are well-established risk factors of Alzheimer's disease (AD). In the brains of patients with AD and model mice, diabetes-related factors have been implicated in the pathological changes of AD. However, the molecular mechanistic link between the peripheral metabolic state and AD pathophysiology have remained elusive. Endoplasmic reticulum (ER) stress is known as one of the major contributors to the metabolic abnormalities in obesity and diabetes. Interventions aimed at reducing ER stress have been shown to improve the systemic metabolic abnormalities, although their effects on the AD pathology have not been extensively studied. OBJECTIVES We examined whether interventions targeting ER stress attenuate the obesity/diabetes-induced Aβ accumulation in brains. We also aimed to determine whether ER stress that took place in the peripheral tissues or central nervous system was more important in the Aβ neuropathology. Furthermore, we explored if age-related metabolic abnormalities and Aβ accumulation could be suppressed by reducing ER stress. METHODS APP transgenic mice (A7-Tg), which exhibit Aβ accumulation in the brain, were used as a model of AD to analyze parameters of peripheral metabolic state, ER stress, and Aβ pathology in the brain. Intraperitoneal or intracerebroventricular administration of taurodeoxycholic acid (TUDCA), a chemical chaperone, was performed in high-fat diet (HFD)-fed A7-Tg mice for ~1 month, followed by analyses at 9 months of age. Mice fed a normal diet were treated with TUDCA by drinking water for 4 months and intraperitoneally for 1 month in parallel, and analyzed at 15 months of age. RESULTS Intraperitoneal administration of TUDCA suppressed ER stress in the peripheral tissues and ameliorated the HFD-induced obesity and insulin resistance. Concomitantly, Aβ levels in the brain were significantly reduced. In contrast, intracerebroventricular administration of TUDCA had no effect on the Aβ levels. Peripheral administration of TUDCA was also effective against the age-related obesity and insulin resistance, and markedly reduced amyloid accumulation. CONCLUSIONS Interventions that target peripheral ER stress might be beneficial therapeutic and prevention strategies against brain Aβ pathology associated with metabolic overload and aging.
Collapse
Affiliation(s)
- T Ochiai
- Tomoko Wakabayashi, Takeshi Iwatsubo, Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan, Tel: +81-3-5841-3541, Fax: +81-3-5841-3613 ,
| | | | | | | | | | | | | |
Collapse
|
2
|
Brown R, Imawari M, Izumi N, Osaki Y, Bentley R, Baykal T, Ochiai T, Kano T. Abstract No. 617 Lusutrombopag reliably increases platelets regardless of baseline platelet counts in thrombocytopenic chronic liver disease patients undergoing planned invasive procedures: results of two phase 3 trials. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
3
|
Brown R, Imawari M, Izumi N, Osaki Y, Ochiai T, Kano T, Bentley R, Peck-Radosavljevic M. Abstract No. 615 Lusutrombopag is a safe and efficacious treatment option for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures: integrated analysis of two phase 3 trials. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
4
|
Brown R, Izumi N, Kano T, Ochiai T, Kurosaki M, Violi F, Shrestha P. Abstract No. 616 Lusutrombopag is a safe treatment option for thrombocytopenia in patients with chronic liver disease undergoing a planned invasive procedure: pooled safety analysis from three studies. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
5
|
Inaba M, Ochiai T, Ohara K, Kato R, Maki T, Ohashi T, Kawarada H. Correlation between the Carbon Nanotube Growth Rate and Byproducts in Antenna-Type Remote Plasma Chemical Vapor Deposition Observed by Vacuum Ultraviolet Absorption Spectroscopy. Small 2019; 15:e1901504. [PMID: 31348615 DOI: 10.1002/smll.201901504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 06/28/2019] [Indexed: 06/10/2023]
Abstract
For sp2 or sp3 carbon material growth, it is important to investigate the precursors or intermediates just before growth. In this study, the density of ethylene (C2 H4 ) outside the plasma discharge space and just before reaching the carbon nanotube (CNT) growth region is investigated by vacuum ultraviolet absorption spectroscopy for plasma discharge in an antenna-type remote plasma chemical vapor deposition with a CH4 /H2 system, with which the growth of very long (≈0.5 cm) CNT forests is achieved. Single-wall CNT forests have the potential for application as electrodes in battery cells, vertical wiring for high current applications, and thermal interface materials. It is observed that the plasma discharge decomposes the CH4 source gas and forms C2 Hx species, which reversibly reform to C2 H4 in the plasma-off state. In addition, the density of the formed C2 H4 has a strong correlation to the CNT growth rate. Therefore, the C2 H4 density is a good indicator of the density of C2 Hx species for CNT growth in the CH4 /H2 plasma system.
Collapse
Affiliation(s)
- Masafumi Inaba
- Graduate School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku, Tokyo, 169-8555, Japan
- Institute of Materials and Systems for Sustainability, Nagoya University, Furo-cho, Chikusa, Nagoya, 464-8603, Japan
| | - Takumi Ochiai
- Graduate School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku, Tokyo, 169-8555, Japan
| | - Kazuyoshi Ohara
- Graduate School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku, Tokyo, 169-8555, Japan
| | - Ryogo Kato
- Graduate School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku, Tokyo, 169-8555, Japan
| | - Tasuku Maki
- Graduate School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku, Tokyo, 169-8555, Japan
| | - Toshiyuki Ohashi
- Graduate School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku, Tokyo, 169-8555, Japan
| | - Hiroshi Kawarada
- Graduate School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku, Tokyo, 169-8555, Japan
- Institute of Materials and Systems for Sustainability, Nagoya University, Furo-cho, Chikusa, Nagoya, 464-8603, Japan
- The Kagami Memorial Laboratory for Materials Science and Technology, Waseda University, 2-8-26 Nishiwaseda, Shinjuku, Tokyo, 169-0051, Japan
| |
Collapse
|
6
|
Abe Y, Sakuyama N, Sato T, Kishine K, Nagayasu K, Nakatani A, Kitajima M, Watanabe T, Nishimura K, Ochiai T, Nagaoka I. Evaluation of the 5-fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy. Mol Clin Oncol 2019; 11:289-295. [PMID: 31396387 DOI: 10.3892/mco.2019.1893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 06/14/2019] [Indexed: 11/05/2022] Open
Abstract
5-Fluorouracil (5-FU) dosing has traditionally been based on the body surface area (BSA) in colorectal cancer treatment. However, there is accumulating evidence that dosing based on BSA may be of limited use. The purpose of the present study was to evaluate the changes in 5-FU plasma levels and tumor response as well as the severity of adverse events in patients with cancer treated with 5-FU combined chemotherapy. The dosing amount of 5-FU was determined based on the BSA. Blood samples were collected, and 5-FU plasma levels in 15 patients with colorectal cancer were measured three times (0, 22 and 40 h before and after the start of infusion) during constant-infusion of 5-FU for 46 h by an immunoassay. 5-FU plasma levels were significantly higher at 22 and 40 h compared with at 0 h (P<0.001), when all 15 patients were analyzed. Notably, the tumor response of the partial response/stable disease group showed significant increases in 5-FU plasma levels at 40 h compared with at 22 h (P<0.01), while the progressive disease group showed no significant increase. In addition, the 5-FU plasma level in the adverse event level of grade ≥2 was higher than that of grade <2 at 40 h after the start of infusion. Collectively, these observations indicated that during continuous infusion of 5-FU, the 5-FU plasma level increased significantly, and the tumor response (such as partial response, stable or progressive disease) may be influenced by the increase of 5-FU plasma level from the start of infusion. Therefore, the 5-FU plasma level may be a predictive factor for maximizing the tumor response and minimizing the risk of severe adverse events.
Collapse
Affiliation(s)
- Yu Abe
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan.,Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
| | - Naoki Sakuyama
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Tsuyoshi Sato
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kenji Kishine
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kiichi Nagayasu
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Akinori Nakatani
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Masayuki Kitajima
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Tomoo Watanabe
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kazuhiko Nishimura
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Isao Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
| |
Collapse
|
7
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Nagayasu K, Sakuyama N, Sato T, Kishine K, Abe Y, Nagaoka I. Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett 2019; 17:1842-1850. [PMID: 30675246 PMCID: PMC6341756 DOI: 10.3892/ol.2018.9805] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2018] [Accepted: 11/20/2018] [Indexed: 12/18/2022] Open
Abstract
In recent studies, better clinical outcomes for patients with left-sided colon cancer (CC) compared with right-sided CC have been reported; however, in such investigations, the chemotherapy regimens included molecular-targeting agents. To the best of our knowledge, the impact of primary tumor location as a predictive factor in patients suffering from CC treated with cytotoxic anticancer agents alone has not been investigated. The aim of the present study was to determine the impact of the primary tumor location as a predictive factor of patients undergoing the following cytotoxic anticancer agent regimens: Leucovorin and fluorouracil + oxaliplatin (FOLFOX) or Leucovorin and fluorouracil + irinotecan (FOLFIRI), using the collagen gel droplet-embedded drug sensitivity test (CD-DST). Between March 2008 and April 2017, tumor specimens were obtained from 133 patients suffering from colorectal cancer (CRC) who had not received preoperative chemotherapy. CD-DST was performed and the growth inhibition rate (IR) was determined in FOLFOX and FOLFIRI regimens. The associations between tumor location and IR values for each condition were evaluated. In the present study, the prognosis of patients receiving palliative chemotherapy as well as treatment with molecularly-targeted agents was also investigated. There were no significant differences in the IRs (%) of the two regimens using CD-DST for right-sided tumors compared with left-sided tumors, including or excluding the rectum. The median survival times of patients with right CC and left CC who had received palliative chemotherapy and treatment with molecularly-targeted agents were 960 and 1,348 days, respectively. Primary tumor location did not represent a predictive factor for the efficacy of treatment with cytotoxic anticancer agent regimens using CD-DST. However, patients suffering from left-sided CC were revealed to exhibit better clinical outcomes compared with patients suffering from right-sided CC when molecularly-targeted agent regimens were administered. Therefore, the results of the present study suggested that molecularly-targeted agents rather than cytotoxic anticancer agents may result in improved clinical outcomes for patients with CRC suffering from left-sided tumors.
Collapse
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kazuhiko Nishimura
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Tomoo Watanabe
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Masayuki Kitajima
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Akinori Nakatani
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kiichi Nagayasu
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Naoki Sakuyama
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Tsuyoshi Sato
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kenji Kishine
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Yu Abe
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Isao Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| |
Collapse
|
8
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Nagayasu K, Sakuyama N, Sato T, Kishine K, Abe Y, Nagaoka I. Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett 2018; 14:6045-6052. [PMID: 30675246 DOI: 10.3892/ol.2017.6960] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Accepted: 02/23/2017] [Indexed: 12/17/2022] Open
Abstract
In recent studies, better clinical outcomes for patients with left-sided colon cancer (CC) compared with right-sided CC have been reported; however, in such investigations, the chemotherapy regimens included molecular-targeting agents. To the best of our knowledge, the impact of primary tumor location as a predictive factor in patients suffering from CC treated with cytotoxic anticancer agents alone has not been investigated. The aim of the present study was to determine the impact of the primary tumor location as a predictive factor of patients undergoing the following cytotoxic anticancer agent regimens: Leucovorin and fluorouracil + oxaliplatin (FOLFOX) or Leucovorin and fluorouracil + irinotecan (FOLFIRI), using the collagen gel droplet-embedded drug sensitivity test (CD-DST). Between March 2008 and April 2017, tumor specimens were obtained from 133 patients suffering from colorectal cancer (CRC) who had not received preoperative chemotherapy. CD-DST was performed and the growth inhibition rate (IR) was determined in FOLFOX and FOLFIRI regimens. The associations between tumor location and IR values for each condition were evaluated. In the present study, the prognosis of patients receiving palliative chemotherapy as well as treatment with molecularly-targeted agents was also investigated. There were no significant differences in the IRs (%) of the two regimens using CD-DST for right-sided tumors compared with left-sided tumors, including or excluding the rectum. The median survival times of patients with right CC and left CC who had received palliative chemotherapy and treatment with molecularly-targeted agents were 960 and 1,348 days, respectively. Primary tumor location did not represent a predictive factor for the efficacy of treatment with cytotoxic anticancer agent regimens using CD-DST. However, patients suffering from left-sided CC were revealed to exhibit better clinical outcomes compared with patients suffering from right-sided CC when molecularly-targeted agent regimens were administered. Therefore, the results of the present study suggested that molecularly-targeted agents rather than cytotoxic anticancer agents may result in improved clinical outcomes for patients with CRC suffering from left-sided tumors.
Collapse
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kazuhiko Nishimura
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Tomoo Watanabe
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Masayuki Kitajima
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Akinori Nakatani
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kiichi Nagayasu
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Naoki Sakuyama
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Tsuyoshi Sato
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kenji Kishine
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Yu Abe
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Isao Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| |
Collapse
|
9
|
Onoe A, Matsuura D, Terui T, Morikawa H, Fujii M, Ochiai T. Erythematous lesion with peripheral purpura on the face. Clin Exp Dermatol 2018; 44:428-431. [DOI: 10.1111/ced.13750] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/06/2018] [Indexed: 12/27/2022]
Affiliation(s)
- A. Onoe
- Department of Dermatology Nihon University Hospital TokyoJapan
| | - D. Matsuura
- Department of Dermatology Nihon University Hospital TokyoJapan
| | - T. Terui
- Division of Dermatological Science Department of Dermatology Nihon University School of Medicine Tokyo Japan
| | | | - M. Fujii
- Department of Digestive Surgery Nihon University Hospital Tokyo Japan
| | - T. Ochiai
- Department of Dermatology Nihon University Hospital TokyoJapan
| |
Collapse
|
10
|
Ochiai T, Tomiyama H, Ikebe H, Fujii S, Kimura K, Matsumoto C, Shiina K, Chikamori D. 421Effect of wave reflection and arterial stiffness on the risk of development of hypertension in Japanese men. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Ochiai
- Tokyo Medical University Ibaraki Medical Center, The Department of Cardiology, Ibaraki, Japan
| | - H Tomiyama
- Tokyo Medical University, The Department of Cardiology, Tokyo, Japan
| | - H Ikebe
- Tokyo Medical University, The Department of Cardiology, Tokyo, Japan
| | - S Fujii
- Tokyo Medical University, The Department of Cardiology, Tokyo, Japan
| | - K Kimura
- Tokyo Medical University Ibaraki Medical Center, The Department of Cardiology, Ibaraki, Japan
| | - C Matsumoto
- Tokyo Medical University, The Department of Cardiology, Tokyo, Japan
| | - K Shiina
- Tokyo Medical University, The Department of Cardiology, Tokyo, Japan
| | - D Chikamori
- Tokyo Medical University, The Department of Cardiology, Tokyo, Japan
| |
Collapse
|
11
|
Hasegawa H, Okabayashi K, Tsuruta M, Koike J, Funahashi K, Yokomizo H, Yoshimatsu K, Kan H, Yamada T, Ishida H, Ishibashi K, Saida Y, Enomoto T, Katsumata K, Koda K, Ochiai T, Sakamoto K, Ogawa S, Itabashi M, Kameoka S. Updated survival results of FACT trial: Multicenter phase II trial of neoadjuvant chemotherapy with mFOLFOX6 for stage II/III rectal cancer with a T3/T4 tumor. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Kawai M, Komiyama H, Hosoya M, Okubo H, Fujii T, Yokoyama N, Sato C, Ueyama T, Okuzawa A, Goto M, Kojima Y, Takahashi M, Sugimoto K, Ishiyama S, Munakata S, Ogura D, Niwa SI, Tomiki Y, Ochiai T, Sakamoto K. Impact of chromosome 17q deletion in the primary lesion of colorectal cancer on liver metastasis. Oncol Lett 2016; 12:4773-4778. [PMID: 28101224 DOI: 10.3892/ol.2016.5271] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Accepted: 03/01/2016] [Indexed: 01/15/2023] Open
Abstract
Colorectal cancer is a prevalent malignancy worldwide, and investigations are required to elucidate the underlying carcinogenic mechanisms. Amongst these mechanisms, de novo carcinogenesis and the adenoma to carcinoma sequence, are the most understood. Metastasis of colorectal cancer to the liver often results in fatality, therefore, it is important for any associated risk factors to be identified. Regarding the treatment of the disease, it is important to manage not only the primary colorectal tumor, but also the liver metastases. Previously, through gene variation analysis, chromosomal loss has been indicated to serve an important role in liver metastasis. Such analysis may aid in the prediction of liver metastasis risk, alongside individual responses to treatment, thus improving the management of colorectal cancer. In the present study, we aimed to clarify a cause of the liver metastasis of colorectal cancer using comparative genomic hybridization analysis. A total of 116 frozen samples were analyzed from patients with advanced colorectal cancer that underwent surgery from 2004 to 2011. The present study analyzed mutations within tumor suppressor genes non-metastatic gene 23 (NM23), deleted in colorectal carcinoma (DCC) and deleted in pancreatic carcinoma, locus 4 (DPC4), which are located on chromosomes 17 and 18 and have all been reported to affect liver metastasis of colorectal cancer. The association between chromosomal abnormalities (duplication and deletion) and liver metastasis of colorectal cancer was evaluated using comparative genomic hybridization. Cluster analysis indicated that the group of patients lacking the long arm of chromosome 17 demonstrated the highest rate of liver metastasis. No significant association was observed between the frequency of liver metastases for synchronous and heterochronous colorectal cancer cases and gene variation (P=0.206). However, when these liver metastasis cases were divided into the synchronous and heterochronous types, the ratio of each was significantly different between gene variation groups, classified by the existence of the 17q deletion (P=0.023). These results indicate that the deletion of 17q may act as a predictive marker of liver metastasis in postoperative states.
Collapse
Affiliation(s)
- Masaya Kawai
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Hiromitsu Komiyama
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Masaki Hosoya
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Haruna Okubo
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Tomoaki Fujii
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Norihiko Yokoyama
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Chiyo Sato
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Takae Ueyama
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Atsushi Okuzawa
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Michitoshi Goto
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Yutaka Kojima
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Makoto Takahashi
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Kiichi Sugimoto
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Shun Ishiyama
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Shinya Munakata
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Dai Ogura
- Link Genomics Inc., Tokyo 103-0012, Japan
| | | | - Yuichi Tomiki
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Takumi Ochiai
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| | - Kazuhiro Sakamoto
- Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| |
Collapse
|
13
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Sato T, Kishine K, Nagaoka I, Futagawa S. Personalized first-line chemotherapy for advanced colorectal cancer using the collagen gel droplet-embedded culture drug sensitivity test. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e14523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Kazuhiko Nishimura
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Tomoo Watanabe
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Masayuki Kitajima
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Akinori Nakatani
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Tsuyoshi Sato
- Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Kennji Kishine
- Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Isao Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo, Japan
| | - Shunji Futagawa
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| |
Collapse
|
14
|
Enomoto T, Saida Y, Takabayashi K, Nagao J, Koike J, Funahashi K, Yoshimatsu K, Yokomizo H, Kan H, Yamada T, Ishida H, Ishibashi K, Katsumata K, Hasegawa H, Koda K, Ochiai T, Sakamoto K, Ogawa S, Itabashi M, Kameoka S. Multicenter phase II trial of neoadjuvant chemotherapy with mFOLFOX6 for stage II/III rectal cancer with a T3/T4 tumor FACT trial. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.3_suppl.713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
713 Background: The efficacy and safety of neoadjuvant chemotherapy with mFOLFOX6 for stage II/III rectal cancer patients with a T3/T4 tumor is still unknown. Methods: Inclusion criteriain this study are as follows: Stage II/III (Ra/Rb) rectal cancer patients with a T3/T4 tumor. The primary endpoint is preoperative response rate, and the secondary endpoints are histological effect, R0 resection rate, pCR rate, down-staging rate, neoadjuvant therapy completion rate, toxicity, the incidence of postoperative complications, and 3-year disease-free survival. Computed tomography was performed after 4 courses of mFOLFOX6. Patients with disease progression (DP) underwent resection of the primary lesion, while those without DP received another 2 courses of treatment. Treatment was discontinued when resection was not possible in patients with DP. Results: Registered patients totaled 53 with a mean age of 60 (38–77). The number of patients with T3 and T4 tumors was 42 and 10, and patients at stages II and III were 10 and 42, respectively. One patient withdrew due to consent retraction. Median relative dose intensity of mFOLFOX6 therapy was 93.2% for L-OHP, 5-FU, and l-LV. Treatment completion was achieved in 96.2% and 84.6% for 4 and 6 courses, respectively, and withdrawal was due to patient’s discretion, not adverse events. Preoperative response rate was 51%. Surgery was performed in 78.8% of patients. Serious (grade ≥3) toxicity included neutropenia (n=5), leukopenia (n=1), thrombocytopenia (n=1), febrile neutropenia (n=1), nausea (n=1), vomiting (n=1), and peripheral neuropathy (n=2). The rates of R0 resection, pCR, and sphincter preservation were 91.0%, 10.3%, and 82.9%. The down staging rate was calculated as 2%. The median follow-up after surgery was 18.0 months. Median DFS was 17.3 months, and 1-year disease-free survival was 78.8%. Median OS was 22.0 months, and 1-year overall survival was 95.7%. Postoperative complications included suture failure (n=3), wound infection (n=2), pneumonia (n=1), and intestinal obstruction (n=1). Conclusions: Neoadjuvant chemotherapy using mFOLFOX6 is a safe and efficacious treatment option for rectal cancer, especially locally advanced disease. Clinical trial information: UMIN000006583.
Collapse
Affiliation(s)
- Toshiyuki Enomoto
- Department of Surgery, Toho University Ohashi Medical Center, Tokyo, Japan
| | - Yoshihisa Saida
- Department of Surgery, Toho University Ohashi Medical Center, Tokyo, Japan
| | | | - Jiro Nagao
- Department of Surgery, Toho University Ohashi Medical Center, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Murakami H, Yazaki Y, Seo S, Ochi T, Okawada M, Doi T, Miyano G, Koga H, Lane GJ, Ochiai T, Yamataka A. A single surgeon's experience of 65 cases of penoplasty for congenital megaprepuce, with special reference to mid- to long-term follow-up. Pediatr Surg Int 2015; 31:89-92. [PMID: 25319799 DOI: 10.1007/s00383-014-3627-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/07/2014] [Indexed: 10/24/2022]
Abstract
PURPOSE There are few reports about postoperative outcome of penoplasty (PP). We present the results of mid- to long-term follow-up of PP performed for congenital megaprepuce (CMP). METHODS Data from 65 CMP cases treated by PP performed by a single surgeon from 2000 to 2014 were collected prospectively. All cases were treated using the technique reported by Cuckow (Pediatric surgery. Springer, Berlin, pp 543-554, 2006). RESULTS Mean age at PP was 5.9 years (range 0.4-13.9). All cases presented as infants and some 12 cases (18.5 %) had PP when 10 or more years old. There were no intra- and postoperative complications. Mean duration of follow-up was 3.6 years (range 0.1-17.5). Duration of follow-up was 4 years or less in 48 (73.8 %), 5-9 years in 13 (20.0 %), and 10 or more years in 4 (6.2 %). While postoperative penile cosmesis was good in 63/65 (96.9 %) cases without scrotal deformity, 2/65 (3.1 %) had redundant penile skin excised upon the recommendation of the treating surgeon even though the patients and parents were unconcerned. CONCLUSION Mid- to long-term follow-up of our PP cases shows that outcome is cosmetically acceptable and stable.
Collapse
Affiliation(s)
- Hiroshi Murakami
- Department of Pediatric General and Urogenital Surgery, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Hoshino M, Ikarashi N, Hirobe R, Hayashi M, Hiraoka H, Yokobori K, Ochiai T, Kusunoki Y, Kon R, Tajima M, Ochiai W, Sugiyama K. Effects of Menthol on the Pharmacokinetics of Triazolam and Phenytoin. Biol Pharm Bull 2015; 38:454-60. [DOI: 10.1248/bpb.b14-00764] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
| | | | - Ryuta Hirobe
- Department of Clinical Pharmacokinetics, Hoshi University
| | - Mami Hayashi
- Department of Clinical Pharmacokinetics, Hoshi University
| | | | | | - Takumi Ochiai
- Department of Clinical Pharmacokinetics, Hoshi University
| | | | - Risako Kon
- Department of Clinical Pharmacokinetics, Hoshi University
| | | | - Wataru Ochiai
- Department of Clinical Pharmacokinetics, Hoshi University
| | | |
Collapse
|
17
|
Yamaue H, Kubota T, Tanigawa N, Ohyama S, Sakuramoto S, Inada T, Kitagawa Y, Ochiai T, Terashima M, Gotoh M, Yasuda Y, Hara A, Kato H, Matsuyama J, Kodera Y, Nashimoto A, Yamaguchi T, Takeuchi M, Fujii M, Nakajima T. Exploratory Phase Ii Trial Assessing Relevance of in Vitro Chemosensitivity Test As a Predictor of Survival in Gastric Cancer Undergoing Adjuvant Chemotherapy (Jaccro-Gc04). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Yokomizo H, Yoshimatsu K, Koike J, Funahashi K, Kan H, Yamada T, Ishida H, Ishibashi K, Saida Y, Enomoto T, Katsumata K, Hasegawa H, Koda K, Ochiai T, Sakamoto K, Nakayama M, Naritaka Y, Ogawa S, Itabashi M, Kameoka S. Multicenter Phase Ii Trial of Neoadjuvant Chemotherapy with Mfolfox6 for Stage Ii/Iii Rectal Cancer with a T3/T4 Tumor Fact Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.91] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Yamaguchi Y, Ochiai T, Hashizume T, Kobayashi R, Ando T. Assosiation of inflammasome in periodontal desease and atherosclerosis induced by Porphyromonas gingivalis oral infection. J Oral Maxillofac Surg 2014. [DOI: 10.1016/j.joms.2014.06.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
20
|
Yoshimura K, Ishii N, Hamada T, Abe T, Ono F, Hashikawa K, Fukuda S, Ohyama B, Koga H, Sogame R, Teye K, Ochiai T, Nakajima H, Nakajima K, Iijima S, Kanzaki M, Kojima K, Nagatani T, Fujimoto W, Karashima T, Nakama T, Ohata C, Furumura M, Tsuruta D, Hashimoto T. Clinical and immunological profiles in 17 Japanese patients with drug‐induced pemphigus studied at Kurume University. Br J Dermatol 2014; 171:544-53. [DOI: 10.1111/bjd.12925] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/23/2013] [Indexed: 11/30/2022]
Affiliation(s)
- K. Yoshimura
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - N. Ishii
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - T. Hamada
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - T. Abe
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - F. Ono
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - K. Hashikawa
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - S. Fukuda
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - B. Ohyama
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - H. Koga
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - R. Sogame
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - K. Teye
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - T. Ochiai
- Department of Dermatology Surugadai Nihon University Hospital Tokyo Japan
| | - H. Nakajima
- Department of Dermatology Kochi University School of Medicine Kochi Japan
| | - K. Nakajima
- Department of Dermatology Kochi University School of Medicine Kochi Japan
| | - S. Iijima
- Department of Dermatology Mito Saiseikai General Hospital Mito Ibaraki Japan
| | - M. Kanzaki
- Department of Dermatology Mito Saiseikai General Hospital Mito Ibaraki Japan
| | - K. Kojima
- Department of Dermatology Kanazawa Medical University School of Medicine Ishikawa Japan
| | - T. Nagatani
- Department of Dermatology Hachioji Medical Center of Tokyo Medical University Tokyo Japan
| | - W. Fujimoto
- Department of Dermatology Kawasaki Medical School of Medicine Okayama Japan
| | - T. Karashima
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - T. Nakama
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - C. Ohata
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - M. Furumura
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| | - D. Tsuruta
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
- Department of Dermatology Osaka City University Graduate School of Medicine Osaka Japan
| | - T. Hashimoto
- Department of Dermatology Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology 67 Asahimachi Kurume Fukuoka 830‐0011 Japan
| |
Collapse
|
21
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Sato T, Kishine K, Futagawa S, Mashiko S, Nagaoka I. Mechanism underlying the transient increase of serum iron during FOLFOX/FOLFIRI therapy. Mol Clin Oncol 2014; 2:968-972. [PMID: 25279183 DOI: 10.3892/mco.2014.385] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2014] [Accepted: 07/09/2014] [Indexed: 12/21/2022] Open
Abstract
In patients with advanced colorectal cancer (CRC), a transient significant increase of serum iron is observed during chemotherapy with leucovorin and fluorouracil plus oxaliplatin (FOLFOX) or leucovorin and fluorouracil plus irinotecan (FOLFIRI). Serum iron may be a useful and convenient predictor of the response to chemotherapy; however, the mechanism underlying its increase has not been fully elucidated. Accordingly, the mechanism underlying the elevation of serum iron during chemotherapy was investigated in 20 patients with advanced CRC who were treated between September, 2012 and July, 2013. The levels of iron, ferritin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), hemoglobin (Hb), hepcidin-25, interleukin (IL)-6 and soluble transferrin receptor (sTfR) were measured before and 48 h after chemotherapy. The serum levels of iron and hepcidin-25 were found to be significantly increased after chemotherapy (P<0.0001), whereas those of IL-6 were significantly decreased (P=0.0057). There were no significant changes in any of the other parameters. The lack of significant changes in AST, ALT and Hb suggested that the elevation of serum iron was not due to the destruction of hepatocytes, whereas the stable sTfR level suggested no destruction of erythroblasts. Hepcidin-25 regulates iron metabolism and decreases serum iron levels; it is increased by an iron load and IL-6, but is decreased under anemic or hypoxic conditions. The suppression of erythropoiesis increases serum iron levels and chemotherapy suppresses erythropoiesis. As serum iron and hepcidin-25 were both significantly increased and IL-6 was significantly decreased, with no significant changes in sTfR, it appears that the elevation of serum iron during chemotherapy may be secondary to reduced iron consumption by erythropoiesis, leading to increased expression of hepcidin-25 and suppression of Il-6 via negative feedback.
Collapse
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kazuhiko Nishimura
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Tomoo Watanabe
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Masayuki Kitajima
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Akinori Nakatani
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Tsuyoshi Sato
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kenji Kishine
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Shunji Futagawa
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Satomi Mashiko
- Department of Pharmacy, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Isao Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| |
Collapse
|
22
|
Ochiai T, Umeki M, Miyake H, Iida T, Okumura M, Ohno K, Sakamoto M, Miyoshi N, Takahashi M, Tsumura H, Tokunaga Y, Naitou H, Fukui T. Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. Oncol Rep 2014; 32:887-92. [PMID: 24994673 PMCID: PMC4121408 DOI: 10.3892/or.2014.3299] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2014] [Accepted: 05/13/2014] [Indexed: 01/05/2023] Open
Abstract
Although 5-fluorouracil (5-FU) is an important drug for colorectal cancer (CRC) treatment, no useful biomarker is currently available to predict treatment response. Since 5-FU is converted into active or inactive forms by orotate phosphoribosyltransferase (OPRT) or dihydropyrimidine dehydrogenase (DPD), a correlation between these enzymes and response to 5-FU has been suggested. However, such a correlation has not been investigated prospectively. Therefore, in the present study, we aimed to prospectively evaluate whether OPRT and DPD were predictive factors of the response to 5-FU treatment in patients with resectable CRC. The present investigation was designed as a multicenter prospective cohort study. OPRT and DPD activities were assessed in biopsy samples, obtained surgically from patients with resectable CRC. The OPRT/DPD ratio was calculated and the cut-off values for this ratio were determined for 5-year disease-free survival (DFS) and overall survival (OS). Patients were treated with 5-FU/leucovorin (LV) regimens and oral 5-FU. The endpoint of this study was the correlation between the OPRT/DPD ratio and 5-year DFS and OS. The cut-off value for the OPRT/DPD ratio was determined by using the maximum χ2 statistic method against 5-year DFS and OS. Sixty-eight patients were enrolled from July 2003 to May 2005. The median follow-up period was 1925 days. The OPRT/DPD ratio cut-off values for 5-year DFS and OS were 0.015 and 0.013, respectively. During the 5-year DFS and OS periods, patients with higher cut-off values had a better prognosis than those with lower ratios (P=0.03 and 0.02, respectively). In conclusion, our results suggest that the OPRT/DPD ratio could be a predictive factor for response to 5-FU/LV adjuvant chemotherapy.
Collapse
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Masahiko Umeki
- Department of Surgery, Hyogo Prefectural Awaji Medical Center, Hyogo 656-0021, Japan
| | - Hiroshi Miyake
- Department of Surgery, Kasukabe Municipal Hospital, Saitama 344-0067, Japan
| | - Tatsumi Iida
- Department of Surgery, Nishimino Kosei Hospital, Gifu 503-131, Japan
| | - Minoru Okumura
- Department of Surgery, Hitachi General Hospital, Ibaragi 317-0077, Japan
| | - Kazuhide Ohno
- Department of Surgery, Matsudo City Hospital, Chiba 271-0064, Japan
| | - Masashi Sakamoto
- Department of Surgery, Mitsui Memorial Hospital, Tokyo 101-8643, Japan
| | - Nobukazu Miyoshi
- Department of Surgery, Kure Kyosai Hospital, Hiroshima 737-0811, Japan
| | - Masahiko Takahashi
- Department of Surgery, Hokkaido P.W.F.A.C Asahikawa-Kosei General Hospital, Hokkaido 078-8211, Japan
| | - Hidenori Tsumura
- Department of Surgery, Koshigaya Municipal Hospital, Saitama 343-0023, Japan
| | - Yukihiko Tokunaga
- Department of Surgery, Japanpost Osaka-kita Teishin Hospital, Osaka 530-0016, Japan
| | - Haruhiko Naitou
- Department of Surgery, Hokkaido Cancer Center, Hokkaido 003-0804, Japan
| | - Takuji Fukui
- Department of Surgery, Kariya Toyota General Hospital, Aichi 448-8505, Japan
| |
Collapse
|
23
|
Shiozaki A, Fujiwara H, Murayama Y, Komatsu S, Kuriu Y, Ikoma H, Nakanishi M, Ichikawa D, Okamoto K, Ochiai T, Kokuba Y, Otsuji E. Perioperative outcomes of esophagectomy preceded by the laparoscopic transhiatal approach for esophageal cancer. Dis Esophagus 2014; 27:470-8. [PMID: 23088181 DOI: 10.1111/j.1442-2050.2012.01439.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
This study was designed to determine the efficacy of esophagectomy preceded by the laparoscopic transhiatal approach (LTHA) with regard to the perioperative outcomes of esophageal cancer. The esophageal hiatus was opened by hand-assisted laparoscopic surgery, and carbon dioxide was introduced into the mediastinum. Dissection of the distal esophagus was performed up to the level of the tracheal bifurcation. En bloc dissection of the posterior mediastinal lymph nodes was performed using LTHA. Next, cervical lymphadenectomy, reconstruction via a retrosternal route with a gastric tube and anastomosis from a cervical approach were performed. Finally, a small thoracotomy (around 10 cm in size) was made to extract the thoracic esophagus and allow upper mediastinal lymphadenectomy to be performed. The treatment outcomes of 27 esophageal cancer patients who underwent LTHA-preceding esophagectomy were compared with those of 33 patients who underwent the transthoracic approach preceding esophagectomy without LTHA (thoracotomy; around 20 cm in size). The intrathoracic operative time and operative bleeding were significantly decreased by LTHA. The total operative time did not differ between the two groups, suggesting that the abdominal procedure was longer in the LTHA group. The number of resected lymph nodes did not differ between the two groups. Postoperative respiratory complications occurred in 18.5% of patients treated with LTHA and 30.3% of those treated without it. The increase in the number of peripheral white blood cells and the duration of thoracic drainage were significantly decreased by this method. Our surgical procedure provides a good surgical view of the posterior mediastinum, markedly shortens the intrathoracic operative time, and decreases the operative bleeding without increasing major postoperative complications.
Collapse
Affiliation(s)
- A Shiozaki
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Sato T, Kishine K, Nagaoka I. Mechanism underlying increased serum iron levels during FOLFOX/FOLFIRI therapy. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e14608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Kazuhiko Nishimura
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Tomoo Watanabe
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Masayuki Kitajima
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Akinori Nakatani
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Tsuyoshi Sato
- Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Kennji Kishine
- Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Isao Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
25
|
Koike J, Funahashi K, Yoshimatsu K, Yokomizo H, Kan H, Yamada T, Ishida H, Ishibashi K, Saida Y, Enomoto T, Katsumata K, Hisada M, Hasegawa H, Koda K, Ochiai T, Sakamoto K, Shiokawa H, Ogawa S, Itabashi M, Kameoka S. Neoadjuvant mFOLFOX6 for stage II/III rectal cancer patients with a T3/T4 tumor. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.3554] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Junichi Koike
- Gastroenterological Surgery, Omori Medical Center, Toho University School of Medicine, Tokyo, Japan
| | - Kimihiko Funahashi
- Gastroenterological Surgery, Omori Medical Center, Toho University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Hiroyuki Shiokawa
- Gastroenterological Surgery, Omori Medical Center, Toho University School of Medicine, Tokyo, Japan
| | | | | | | |
Collapse
|
26
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Shibata H, Sato T, Kishine K, Seo S, Okubo S, Futagawa S, Mashiko S, Nagaoka I. Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs. Mol Clin Oncol 2014; 1:805-810. [PMID: 24649250 PMCID: PMC3916199 DOI: 10.3892/mco.2013.136] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2012] [Accepted: 05/15/2013] [Indexed: 12/11/2022] Open
Abstract
Serum iron levels have been reported to increase following the administration of various anticancer drugs. An increase in serum iron levels during therapy with leucovorin and fluorouracil plus oxaliplatin (FOLFOX) or leucovorin and fluorouracil plus irinotecan (FOLFIRI) was also observed. The aim of this study was to investigate the correlation between serum iron levels and prognosis in advanced colorectal cancer (CRC) patients treated with FOLFOX/FOLFIRI ± molecularly-targeted drugs. Serum iron levels were measured prior to and at 48 h after treatment with FOLFOX/FOLFIRI ± molecularly-targeted drugs in 72 advanced CRC patients, all of whom succumbed to the disease between December, 2005 and February, 2012. No patients received radiotherapy. Taking the median rate of increase in serum iron levels as the cut-off value in each therapy, the patients were divided into cohort I (increase rate greater than the cut-off value in at least one therapy) or cohort II (increase rate less than the cut-off value in all therapies). The χ2 test and the t-test were used to compare patient characteristics between the two cohorts. Prognosis was evaluated between the two cohorts using the Kaplan-Meier method, the log-rank test and the Cox proportional hazards regression analysis. No significant bias in patient characteristics (including the frequency of chemotherapy or number of patients treated with molecularly-targeted drugs) was observed between the two cohorts. Serum iron levels were transiently elevated following treatment (P<0.001), returning to baseline within 2 weeks. Median survival time (MST) in cohort I (n=44) and cohort II (n=28) was 430 and 377 days, respectively. The MST was significantly higher in cohort I (P=0.0382). The multivariate analysis identified a small increase in serum iron levels as an independent risk factor for overall survival (OS). These results suggest that serum iron levels may be used as a new predictive factor in FOLFOX/FOLFIRI ± molecularly-targeted drug therapy. Serum iron levels may therefore prove to be a useful and convenient biomarker for OS in CRC patients.
Collapse
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kazuhiko Nishimura
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Tomoo Watanabe
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Masayuki Kitajima
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Akinori Nakatani
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Takashi Inou
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Hideki Shibata
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Tsuyoshi Sato
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Kenji Kishine
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Shougo Seo
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Satoshi Okubo
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Shunji Futagawa
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Satomi Mashiko
- Department of Pharmacy, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan
| | - Isao Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo 113-8421, Japan
| |
Collapse
|
27
|
Ochiai T, Shioya A, Honma H, Saitoh Y, Matsumura S, Ban D, Irie T, Kudo A, Nakamura N, Fujikawa T, Itai A, Tanaka S, Arii S, Yamaoka S, Tanabe M. Combination Treatment of IκB Kinase β Inhibitor IMD-0354 and Gemcitabine Suppresses Oncogenic Proliferation of Pancreatic Cancer Cells. J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Sato T, Kishine K, Okubo S, Futagawa S, Nagaoka I. Serum iron levels potential biomarker in FOLFOX/FOLFIRI with or without molecularly targeted drug therapy. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e14651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14651 Background: We reported an increase in serum iron levels during therapy with FOLFOX or FOLFIRI ± molecularly targeted drugs and a correlation between prognosis and transition of those levels in advanced colorectal cancer (CRC) patients (ASCO; 2009: #e15110, 2011: #e14141, 2012: #e14004). The aims of this prospective cohort study were to establish serum iron levels as a new biomarker in advanced CRC patients undergoing therapy based on this correlation and investigate the mechanism of this increase in serum iron levels. Methods: Eighty-one advanced CRC patients were treated; all died between Dec. 2005 and Nov. 2012; none received radiotherapy; 9 of these patients were undergoing treatment between Sep. 2012 and Nov. 2012. Serum iron levels were measured at before and 48 hr after treatment. Taking the median rate of increase in serum iron levels as the cut-off value in each therapy, the patients were categorized into cohort I (increase rate over cut-off value in at least one therapy) or cohort II (increase rate under cut-off value in all therapies). Prognosis was evaluated between the two. Hepcidin (Hepc), Interleukin-6 (IL-6) and soluble transferrin receptor (sTfR) were measured at before and 48 hr after treatment. Results: No significant bias in patient characteristics (including in frequency or type of regimen) was observed between the two cohorts. Serum iron levels transiently increased after treatment (p<0.001), then returning to baseline within 2 weeks. Median survival time (MST) in cohort I (n: 50) and cohort II (n: 31) was 437 and 378 days, respectively, with MST significantly better in cohort I (p=0.0417). Multivariate analysis identified Dukes’ stage, recurrence type, and serum iron level as independent risk factors for overall survival (OS). Hepc significantly increased after treatment (p<0.001), with no significant change in IL-6 or sTfR. Conclusions: Serum iron levels offer potential as an extremely useful and convenient biomarker for OS in CRC patients. While Hepc significantly increased, no significant decrease was observed in sTfR after treatment. This suggests that serum iron levels increased as a result of a treatment-induced reduction in iron consumption by bone marrow.
Collapse
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Kazuhiko Nishimura
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Tomoo Watanabe
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Masayuki Kitajima
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Akinori Nakatani
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Tsuyoshi Sato
- Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Kennji Kishine
- Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Satoshi Okubo
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Shunji Futagawa
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Isao Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
29
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Tsuji M, Nakatani A, Nakayama N, Marusasa T, Mashiko S, Nagaoka I, Futagawa S. Evaluation of the individual 50% inhibitory area under the concentration curve of 5-fluorouracil based on the collagen gel droplet embedded culture drug sensitivity test in colorectal cancer. Mol Med Rep 2012; 2:405-9. [PMID: 21475842 DOI: 10.3892/mmr_00000113] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We have previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells from colorectal cancer (CRC) patients using the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) under multiple drug concentrations and contact durations. Moreover, the area under the concentration curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR curve, which was approximated to the logarithmic curve. In the present study, we used the AUC-IR curve to calculate the individualized AUCIR50, the AUC value that imparts 50% growth inhibition. Individual AUCIR50 was calculated in CRC patients, and its distribution was evaluated. The cumulative distribution of individual AUCIR50 was regressed over two lines (logarithmic scale). Among the 45 resectable CRC patients, those who achieved more than the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated a trend towards better disease-free survival compared to those who did not achieve AUCIR50. Of the Dukes' D patients (n=10), those who achieved more than twice the individual AUCIR50 during post-operative 5-FU-based chemotherapy demonstrated significantly better survival rates (p=0.05) than those who did not. In this study, the distribution of the individual AUCIR50 suggested that approximately 6% of patients demonstrated very low 5-FU sensitivity. Therefore, the individual AUCIR50 was useful in classifying good, intermediate and poor 5-FU response. Achievement of the individual AUCIR50 may be a prerequisite for individualized 5-FU-based adjuvant chemotherapy. As well, the early achievement of twice the individual AUCIR50 may indicate an improved prognosis in Dukes' D patients. The individual AUCIR50 using CD-DST is useful in determining the individualized chemotherapy of CRC patients, thus CD-DST has the potential to facilitate the establishment of individualized chemotherapy for CRC.
Collapse
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo 125-8512, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Kumagai Y, Yagi M, Aida J, Ishida H, Suzuki S, Hashimoto T, Amanuma Y, Kusano M, Mukai S, Yamazaki S, Iida M, Ochiai T, Matsuura M, Iwakiri K, Kawano T, Hoshihara Y, Takubo K. Detailed features of palisade vessels as a marker of the esophageal mucosa revealed by magnifying endoscopy with narrow band imaging. Dis Esophagus 2012; 25:484-90. [PMID: 22098187 DOI: 10.1111/j.1442-2050.2011.01283.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The palisade vessels present at the distal end of the esophagus are considered to be a landmark of the esophagogastric junction and indispensable for diagnosis of columnar-lined esophagus on the basis of the Japanese criteria. Here we clarified the features of normal palisade vessels at the esophagogastric junction using magnifying endoscopy. We prospectively studied palisade vessels in 15 patients undergoing upper gastrointestinal endoscopy using a GIF-H260Z instrument (Olympus Medical Systems Co., Tokyo, Japan). All views of the palisade vessels were obtained at the maximum magnification power in the narrow band imaging mode. We divided the area in which palisade vessels were present into three sections: the area from the squamocolumnar junction (SCJ) to about 1 cm orad within the esophagus (Section 1); the area between sections 1 and 3 (Section 2); and the area from the upper limit of the palisade vessels to about 1 cm distal within the esophagus (Section 3). In each section, we analyzed the vessel density, caliber of the palisade vessels, and their branching pattern. The vessel density in Sections 1, 2, and 3 was 9.1 ± 2.1, 8.0 ± 2.6, and 3.3 ± 1.3 per high-power field (mean ± standard deviation [SD]), respectively, and the differences were significant between Sections 1 and 2 (P= 0.0086) and between Sections 2 and 3 (P < 0.0001). The palisade vessel caliber in Sections 1, 2, and 3 was 127.6 ± 52.4 µm, 149.6 ± 58.6 µm, and 199.5 ± 75.1 µm (mean ± SD), respectively, and the differences between Sections 1 and 2, and between Sections 2 and 3, were significant (P < 0.0001). With regard to branching form, the frequency of branching was highest in Section 1, and the 'normal Y' shape was observed more frequently than in Sections 2 and 3. Toward the oral side, the frequency of branching diminished, and the frequency of the 'upside down Y' shape increased. The differences in branching form were significant among the three sections (P < 0.0001). These results indicate that the density of palisade vessels is highest near the SCJ, and that towards their upper limit they gradually become more confluent and show an increase of thickness. Within a limited area near the SCJ, observations of branching form suggest that palisade vessels merge abruptly on the distal side. We have demonstrated that palisade vessels are a useful marker for endoscopic recognition of the lower esophagus.
Collapse
Affiliation(s)
- Y Kumagai
- Department of Surgery, Ohta Nishinouchi Hospital, Fukushima, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T, Kishine K, Ochi T, Okubo S, Futagawa S, Mashiko S, Nagaoka I. Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett 2012. [PMID: 23205073 DOI: 10.3892/ol.2012.823] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The leucovorin (FOL) and fluorouracil (5-FU) plus oxaliplatin (l-OHP; FOLFOX) or FOL and 5-FU plus irinotecan (SN-38; FOLFIRI) regimens with or without molecularly-targeted drugs are widely used as first-line chemotherapy in the treatment of advanced colorectal cancer (CRC). Whether FOLFOX or FOLFIRI is administered first is not significant, however, it is essential that full administration of the targeted dosages of all 3 drugs, 5-FU, l-OHP and SN-38, is achieved. However, this is not always possible and second-line chemotherapy must be abandoned in certain cases. Where possible, the most effective regimen should be selected as the first line of treatment. The aim of this study was to determine whether first-line chemotherapy may be individualized using the collagen gel droplet-embedded drug sensitivity test (CD-DST). Specimens of primary tumors were obtained from 43 CRC patients who had received no preoperative chemotherapy. Informed consent to measure drug sensitivity was obtained from all patients. The CD-DST allows evaluation of drug sensitivity using isolated, 3-dimensionally cultured tumor cells in a small collagen gel droplet. The CD-DST was performed and the growth inhibition rate (IR) was obtained under incubation conditions (5-FU with l-OHP at 6.0 and 3.0 μg/ml, or 5-FU with SN-38 at 6.0 and 0.2 μg/ml, respectively, for 24 h). The cumulative distributions of the growth IRs under each condition were evaluated based on the evidence that the clinical response rates to FOLFOX and FOLFIRI were almost the same. Individualization of first-line treatment was possible in all patients, with FOLFOX and FOLFIRI showing higher efficacy in 26 and 15 patients, respectively, and equal efficacy in 2 cases. This method has the potential to facilitate the establishment of individualized first-line chemotherapy for CRC and improve the prognosis in such patients.
Collapse
|
32
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Sakuyama N, Washio M, Kishine K, Sato T, Ochi T, Okubo S, Futagawa S, Nagaoka I. Serum iron levels as new predictive factor in FOLFOX/FOLFIRI with or without molecularly targeted drug therapy. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e14004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14004 Background: An increase in serum iron levels after administration of various anticancer drugs was reported (Follezou et al, NEOPLASMA 1985). We have also reported an increase in serum iron levels during FOLFOX and FOLFIRI therapies (ASCO 2009: #e15110) and a correlation between prognosis and transition of serum iron levels in advanced colorectal cancer (CRC) patients (ASCO 2011: #e14141). The aim of this cohort study was to evaluate the correlation between prognosis and serum iron levels in advanced CRC patients treated with FOLFOX/FOLFIRI ± molecularly targeted drugs. Methods: Serum iron levels were measured before and at 48 hr after treatment (FOLFOX/FOLFIRI ± molecularly targeted drugs) in 69 advanced CRC patients, all of whom died between December 2005 and December 2011. No patients were treated with radiotherapy. Taking the median rate of increase in serum iron levels as the cut-off value in each therapy, the patients were categorized into cohort I (increase rate over cut-off value in at least one therapy) and cohort II (increase rate under the cut-off value in all therapies). Prognosis was evaluated between the two cohorts using the Kaplan-Meier method and the log rank test. Results: No significant bias in patient characteristics was observed between the two cohorts. Serum iron levels transiently increased after treatment (p<0.001), then returning to baseline within 2 weeks. Median survival time (MST) in cohort I (n: 41) and cohort II (n: 28) was 430 and 377 days, respectively. The MST was significantly better in cohort I (p=0.0496). No significant differences were observed in the frequency of chemotherapies or number of patients treated with molecularly targeted drugs between the two cohorts. Conclusions: Cohort I showed a statistically significant better prognosis. The results suggest that serum iron levels could be used as a new predictive factor in FOLFOX/FOLFIRI ± molecularly targeted drug therapy. In Cohort II patients, molecularly targeted drugs should be used positively for further improvement in prognosis.
Collapse
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Kazuhiko Nishimura
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Tomoo Watanabe
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Masayuki Kitajima
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Akinori Nakatani
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Takashi Inou
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Naoki Sakuyama
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Marie Washio
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Kennji Kishine
- Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Tsuyoshi Sato
- Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Takanori Ochi
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Satoshi Okubo
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Shunji Futagawa
- Department of Surgery, Tobu Chiiki Hospital Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | - Isao Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
33
|
Yamada Y, Boskovic S, Aoyama A, Murakami T, Putheti P, Smith RN, Ochiai T, Nadazdin O, Koyama I, Boenisch O, Najafian N, Bhasin M, Colvin RB, Madsen JC, Strom TB, Sachs DH, Benichou G, Cosimi AB, Kawai T. Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. Am J Transplant 2012; 12:330-40. [PMID: 22053723 PMCID: PMC3268945 DOI: 10.1111/j.1600-6143.2011.03795.x] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The presence of alloreactive memory T cells is a major barrier for induction of tolerance in primates. In theory, delaying conditioning for tolerance induction until after organ transplantation could further decrease the efficacy of the regimen, since preexisting alloreactive memory T cells might be stimulated by the transplanted organ. Here, we show that such "delayed tolerance" can be induced in nonhuman primates through the mixed chimerism approach, if specific modifications to overcome/avoid donor-specific memory T-cell responses are provided. These modifications include adequate depletion of CD8+ memory T cells and timing of donor bone marrow administration to minimize levels of proinflammatory cytokines. Using this modified approach, mixed chimerism was induced successfully in 11 of 13 recipients of previously placed renal allografts and long-term survival without immunosuppression could be achieved in at least 6 of these 11 animals.
Collapse
Affiliation(s)
- Y. Yamada
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - S. Boskovic
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - A. Aoyama
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - T. Murakami
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - P. Putheti
- Department of Medicine, Transplant Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02114
| | - R. N. Smith
- Department of pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - T. Ochiai
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - O. Nadazdin
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - I. Koyama
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - O. Boenisch
- Department of Medicine, Renal Division, Brigham and Women’s Hospital, Boston, MA 02114
| | - N. Najafian
- Department of Medicine, Renal Division, Brigham and Women’s Hospital, Boston, MA 02114
| | - M.K. Bhasin
- Department of Medicine, Transplant Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02114
| | - R. B. Colvin
- Department of pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - J. C. Madsen
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - T. B. Strom
- Department of Medicine, Transplant Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02114
| | - D. H. Sachs
- Transplant Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - G. Benichou
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - A. B. Cosimi
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| | - T. Kawai
- Transplant Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
| |
Collapse
|
34
|
Ochiai T, Ohta K, Kumagai Y, Iida M, Yamazaki S, Tanaka S, Arii S. Aggressive Resection of Colorectal Liver Metastases After Approval of Molecular Target-Based Drugs. J Surg Res 2012. [DOI: 10.1016/j.jss.2011.11.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
35
|
Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H, Konishi H, Shiozaki A, Ikoma H, Okamoto K, Ochiai T, Taniguchi H, Otsuji E. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011; 105:1733-40. [PMID: 22045190 PMCID: PMC3242609 DOI: 10.1038/bjc.2011.453] [Citation(s) in RCA: 202] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2011] [Revised: 09/28/2011] [Accepted: 10/05/2011] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Several recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in the plasma/serum. We hypothesised that miR-18a in the plasma is a potential biomarker in patients with pancreatic cancer. METHODS miR-18a is located in the miR-17-92 cluster and reported to be highly expressed in pancreatic cancer tissues. This study was divided into three parts: (1) Confirmation of higher miR-18a levels in primary pancreatic cancer tissues and cell lines than in normal pancreatic tissues and a human fibroblast cell line. (2) Evaluation of the plasma miR-18a assay using quantitative RT-PCR by comparing plasma results obtained from 36 patients with pancreatic cancer and from 30 healthy volunteers. (3) Evaluation of the assay for monitoring tumour dynamics in patients with pancreatic cancer. RESULTS (1) The expression of miR-18a was significantly higher in pancreatic cancer tissues (P=0.012) and pancreatic cancer cell lines (P=0.015) than in normal tissues and fibroblasts. (2) Plasma concentrations of miR-18a were significantly higher in pancreatic cancer patients than in controls (P<0.0001). The value of the area under the receiver-operating characteristic curve (AUC) was 0.9369. (3) Plasma levels of miR-18a were significantly lower in postoperative samples than in preoperative samples (P=0.0077). CONCLUSION Circulating miR-18a might provide new complementary tumour markers for pancreatic cancer.
Collapse
Affiliation(s)
- R Morimura
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - S Komatsu
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - D Ichikawa
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - H Takeshita
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - M Tsujiura
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - H Nagata
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - H Konishi
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - A Shiozaki
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - H Ikoma
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - K Okamoto
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - T Ochiai
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - H Taniguchi
- Department of Surgery, Kyoto Second Red Cross Hospital, 355-5 Kamanzadoori Marutacho Hruobicho, Kamigyo-ku, Kyoto, Japan
| | - E Otsuji
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| |
Collapse
|
36
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Hashiguchi T, Nakatani A, Sakuyama N, Uchida T, Sato T, Kishine K, Futagawa S, Nagaoka I. Serum iron levels as a predictive factor in FOLFOX/FOLFIRI therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Koda K, Miyauchi H, Ochiai T, Yasuda H, Kaiho T, Tanaka N, Yokoi K, Kobayashi S, Matsubara H. Randomized, controlled trial comparing UFT with S-1 as adjuvant therapy for curatively resected stage III colorectal cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
515 Background: Oral anticancer drug, UFT, has recently been reported to improve both overall survival (OS) and relapse-free survival (RFS) for patients with stage III colorectal cancer in Japan. We conducted a randomized clinical trial to compare S-1 with UFT for adjuvant therapy in patients with stage III colorectal cancer. Methods: Patients with stage III colorectal cancer (PS, 0 to 1; age, 20 to 80 years) were randomized to take either UFT (400mg/m2/day, 5days per week) or S-1 (80mg/m2/day, 28days per 6weeks) for 1 year started within 6 weeks following curative resection. The primary endpoint was to investigate relations of relapse-free survival (RFS) and tissue mRNA levels of 5-FU metabolism-related enzymes. The secondary endpoint was over all survival (OS) and safety. Results: Between July 2005 and February 2008, a total of 100 patients were registered from 21 centers. There were no clear intergroup differences in background factors. When patients who relapsed within 1 year postoperatively were excluded, the percentages of patients who took expected dosage of medicine were 73% (30/41) and 72% (33/46) in UFT and S-1 groups, respectively. Grade 3 liver dysfunction (4%) or diarrhea (4%) occurred in UFT group, whereas grade3 to 4 myelosuppression (4%), diarrhea (4%), stomatitis (2%) were observed in S-1 group, but all of them were reversible. With a median follow-up period of 1,250 days, OS in patients of UFT and S-1 groups were 86.6% and 95.9%, respectively (p=0.06). The number of patients who relapsed in rectal cancer was significantly higher in UFT group (11/25) than in S-1 group (4/21, p<0.01). In a multivariate analysis, dihydropyrimidine dehydrogenase (DPD) mRNA level was shown as a factor of the recurrences. And S-1 improved RFS in patients with rectum cancer with high orotate phosphoribosil transferase (OPRT) mRNA level. Conclusions: Oral anticancer drug, S-1, was no less effective than UFT as an adjuvant therapy for stage III colorectal cancer. Tissue levels of both DPD and OPRT mRNA were important parameters for postoperative prognosis in patients with stage III colorectal cancer who take oral 5-FU derivatives for adjuvant therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Koda
- Teikyo University Chiba Medical Center, Ichihara, Japan; Graduate School of Medicine, Chiba University, Chiba, Japan; San-ai Memorial Soga Hospital, Chiba, Japan; Kijitsu Chuo Hospital, Kimitsu, Japan; Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; Asahi Chuo Hospital, Asahi, Japan; Chiba Prefectual Sawara Hospital, Sawara, Japan
| | - H. Miyauchi
- Teikyo University Chiba Medical Center, Ichihara, Japan; Graduate School of Medicine, Chiba University, Chiba, Japan; San-ai Memorial Soga Hospital, Chiba, Japan; Kijitsu Chuo Hospital, Kimitsu, Japan; Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; Asahi Chuo Hospital, Asahi, Japan; Chiba Prefectual Sawara Hospital, Sawara, Japan
| | - T. Ochiai
- Teikyo University Chiba Medical Center, Ichihara, Japan; Graduate School of Medicine, Chiba University, Chiba, Japan; San-ai Memorial Soga Hospital, Chiba, Japan; Kijitsu Chuo Hospital, Kimitsu, Japan; Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; Asahi Chuo Hospital, Asahi, Japan; Chiba Prefectual Sawara Hospital, Sawara, Japan
| | - H. Yasuda
- Teikyo University Chiba Medical Center, Ichihara, Japan; Graduate School of Medicine, Chiba University, Chiba, Japan; San-ai Memorial Soga Hospital, Chiba, Japan; Kijitsu Chuo Hospital, Kimitsu, Japan; Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; Asahi Chuo Hospital, Asahi, Japan; Chiba Prefectual Sawara Hospital, Sawara, Japan
| | - T. Kaiho
- Teikyo University Chiba Medical Center, Ichihara, Japan; Graduate School of Medicine, Chiba University, Chiba, Japan; San-ai Memorial Soga Hospital, Chiba, Japan; Kijitsu Chuo Hospital, Kimitsu, Japan; Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; Asahi Chuo Hospital, Asahi, Japan; Chiba Prefectual Sawara Hospital, Sawara, Japan
| | - N. Tanaka
- Teikyo University Chiba Medical Center, Ichihara, Japan; Graduate School of Medicine, Chiba University, Chiba, Japan; San-ai Memorial Soga Hospital, Chiba, Japan; Kijitsu Chuo Hospital, Kimitsu, Japan; Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; Asahi Chuo Hospital, Asahi, Japan; Chiba Prefectual Sawara Hospital, Sawara, Japan
| | - K. Yokoi
- Teikyo University Chiba Medical Center, Ichihara, Japan; Graduate School of Medicine, Chiba University, Chiba, Japan; San-ai Memorial Soga Hospital, Chiba, Japan; Kijitsu Chuo Hospital, Kimitsu, Japan; Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; Asahi Chuo Hospital, Asahi, Japan; Chiba Prefectual Sawara Hospital, Sawara, Japan
| | - S. Kobayashi
- Teikyo University Chiba Medical Center, Ichihara, Japan; Graduate School of Medicine, Chiba University, Chiba, Japan; San-ai Memorial Soga Hospital, Chiba, Japan; Kijitsu Chuo Hospital, Kimitsu, Japan; Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; Asahi Chuo Hospital, Asahi, Japan; Chiba Prefectual Sawara Hospital, Sawara, Japan
| | - H. Matsubara
- Teikyo University Chiba Medical Center, Ichihara, Japan; Graduate School of Medicine, Chiba University, Chiba, Japan; San-ai Memorial Soga Hospital, Chiba, Japan; Kijitsu Chuo Hospital, Kimitsu, Japan; Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; Asahi Chuo Hospital, Asahi, Japan; Chiba Prefectual Sawara Hospital, Sawara, Japan
| |
Collapse
|
38
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Marusasa T, Hashiguchi T, Uchida T, Sakuyama N, Sato T, Kishine K, Futagawa S, Nagaoka I. Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer. Oncol Lett 2011; 2:309-313. [PMID: 22866082 DOI: 10.3892/ol.2011.251] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2010] [Accepted: 12/22/2010] [Indexed: 12/16/2022] Open
Abstract
We previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells obtained from colorectal cancer (CRC) patients using the collagen gel droplet-embedded culture-drug sensitivity test (CD-DST). Multiple drug concentrations and contact durations, and the area under the concentration curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR curve, which was approximated to the logarithmic curve. Moreover, the individualized AUC(IR50), the AUC value which gives 50% growth inhibition, was calculated using the AUC-IR curve. This study aimed to identify responders/non-responders to 5-FU based on the individual AUC(IR50) obtained with CD-DST in order to establish individualized chemotherapy for CRC patients. The individual AUC(IR50) was calculated from each AUC-inhibition rate regression curve in all patients using the CD-DST. The cumulative distribution of the individual AUC(IR50) in CRC patients was evaluated. The cumulative distribution of the individual AUC(IR50) was regressed over the sigmoid curve (logarithmic scale). The approximate expression was almost exactly y=ab^exp(-cx) (a=0.9739, b=1.7096E-21, c=0.8990, the sum of square residuals, 0.0279). In the 80 cases examined, no notable change was observed in the regression curve when the number of patients increased. A standard curve was obtained describing responders to 5-FU among all CRC patients. From this standard curve, we ascertained that non-responders accounted for approximately 5% of all patients. Moreover, we were able to classify responders into good or intermediate responders to 5-FU. The standard curve describing response to 5-FU in CRC patients offers a useful tool in the establishment of individualized chemotherapy.
Collapse
Affiliation(s)
- Takumi Ochiai
- Department of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Kumagai Y, Kawada K, Yamazaki S, Iida M, Ochiai T, Kawano T, Takubo K. Prospective replacement of magnifying endoscopy by a newly developed endocytoscope, the 'GIF-Y0002'. Dis Esophagus 2010; 23:627-32. [PMID: 20545974 DOI: 10.1111/j.1442-2050.2010.01074.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Endocytoscopy has the potential to reduce the need for histologic examination of biopsy specimens in cases of esophageal squamous cell carcinoma. Up to now, two types of endocytoscope have been used: the probe type and the integrated type. In this study we examined the utility of a newly developed endocytoscope, the 'GIF-Y0002,' which has a single lens allowing consecutive magnification from the conventional endoscopy level up to ×380. Using the GIF-Y0002, we examined 24 examples of normal esophageal mucosa to clarify the appearance of the microvasculature of the normal squamous epithelium in vivo. We also examined 11 cases of esophageal cancer in the same way, employing methylene blue as a vital dye to stain the surface cells. In normal squamous epithelium, we clarified the relationship between the subepithelial capillary network, IPCLs and subepithelial venules. With methylene blue staining, we observed typical squamous cells (low nuclear density and low N/C ratio without nuclear abnormality). When cancerous lesions were observed using lower-power magnification, we were able to visualize their microvascular architecture to the same extent as when conventional magnifying endoscopy was used. Furthermore, at higher magnification, we were able to visualize the features of blood flow in both superficial and advanced cancer. Methylene blue staining revealed an increase of nuclear density in all cases of cancer. The pathologist agreed to omit biopsy histology in 81.8% (9/11) of cancer cases considering the nuclear density and nuclear abnormality. The GIF-Y0002 provides information on cell abnormality in addition to the features revealed by currently available magnifying endoscopy.
Collapse
Affiliation(s)
- Y Kumagai
- Department of Surgery, Ohta Nishinouchi Hospital, Fukushima, Japan.
| | | | | | | | | | | | | |
Collapse
|
40
|
Affiliation(s)
- T Ochiai
- Department of Surgery, Ohta Nishinouchi General Hospital, Koriyama, Fukushima, Japan
| | | | | | | | | |
Collapse
|
41
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Hashiguchi T, Nakatani A, Muraki A, Sakuyama N, Futagawa S, Nagaoka I. Personalized adjuvant chemotherapy for colorectal cancer based on an individual 50% inhibitory area under the concentration curve using collagen gel droplet embedded culture-drug sensitivity test. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Mashiko S, Nagaoka I, Kitajima M, Watanabe T, Nishimura K, Futagawa S, Ochiai T. Evaluation of serum iron levels during FOLFOX4 and FOLFIRI therapies. Exp Ther Med 2010; 1:507-511. [PMID: 22993568 DOI: 10.3892/etm_00000080] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2010] [Accepted: 03/22/2010] [Indexed: 12/27/2022] Open
Abstract
FOLFOX4 and FOLFIRI are effective regimens for the treatment of advanced colorectal cancer, and their use together with molecular targeting drugs has recently become more common. In the present study, we evaluated the changes in the serum iron levels of patients undergoing FOLFOX4 or FOLFIRI therapy alone or in combination with bevacizumab (BV). The serum iron level was increased 48 h after therapy and was restored to baseline 2 weeks afterwards in colorectal cancer patients who received FOLFOX4 or FOLFIRI alone or in combination with BV. This transient increase in serum iron was observed repeatedly during chemotherapy. The serum iron level was 71.66±28.96 μg/dl (mean ± standard deviation) before treatment and significantly increased to 186.82±83.17 μg/dl (p<0.001) 48 h after therapy. A transient increase in serum iron levels was also observed when FOLFIRI was administered to a patient after tumor resection. In contrast, no decrease in blood hemoglobin, no increase in liver enzymes and no increase in urinary iron excretion were observed. Based on these results, it can be concluded that an increase in serum iron may be induced by a transient change in iron distribution within the body after FOLFOX4/FOLFIRI therapy with or without BV.
Collapse
|
43
|
Igari K, Ochiai T, Aihara A, Kumagai Y, Iida M, Yamazaki S. Clinical presentation of obturator hernia and review of the literature. Hernia 2010; 14:409-13. [DOI: 10.1007/s10029-010-0658-z] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2009] [Accepted: 03/28/2010] [Indexed: 12/13/2022]
|
44
|
Ochiai T, Shibukawa Y, Nagayama M, Mundy C, Yasuda T, Okabe T, Shimono K, Kanyama M, Hasegawa H, Maeda Y, Lanske B, Pacifici M, Koyama E. Indian hedgehog roles in post-natal TMJ development and organization. J Dent Res 2010; 89:349-54. [PMID: 20200412 DOI: 10.1177/0022034510363078] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Indian hedgehog (Ihh) is essential for embryonic mandibular condylar growth and disc primordium formation. To determine whether it regulates those processes during post-natal life, we ablated Ihh in cartilage of neonatal mice and assessed the consequences on temporomandibular joint (TMJ) growth and organization over age. Ihh deficiency caused condylar disorganization and growth retardation and reduced polymorphic cell layer proliferation. Expression of Sox9, Runx2, and Osterix was low, as was that of collagen II, collagen I, and aggrecan, thus altering the fibrocartilaginous nature of the condyle. Though a disc formed, it exhibited morphological defects, partial fusion with the glenoid bone surface, reduced synovial cavity space, and, unexpectedly, higher lubricin expression. Analysis of the data shows, for the first time, that continuous Ihh action is required for completion of post-natal TMJ growth and organization. Lubricin overexpression in mutants may represent a compensatory response to sustain TMJ movement and function.
Collapse
Affiliation(s)
- T Ochiai
- Department of Orthopaedic Surgery, Thomas Jefferson University College of Medicine, 1015 Walnut Street, Curtis Building Room 501, Philadelphia, PA 19107, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Nakajima T, Akagawa H, Ochiai T, Hayashi M, Goto S, Taira T, Okada Y. [Intrathecal baclofen therapy for spastic paraparesis due to aortic dissecting aneurysm; recent progress in treatment strategy]. Kyobu Geka 2009; 62:1039-1042. [PMID: 19894566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A 48-year-old man suffered from acute dissection of thoracic aortic aneurysm which eventually led to replacement of the ascending aorta with a tube graft. During this clinical course, circulatory failure in intercostal artery resulted in spinal cord infarction followed by moto-sensory disturbance below Th7 dermatomic area. Seven months later, spasticity with pain in both lower extremities became conspicuous that was uncontrollable by any oral medication. Eventually the patient underwent the implantation of continuous infusion pump for intrathecal baclofen therapy (ITB). The clinical condition was remarkably improved and now has been well controlled. ITB, authorized by Japanese Ministry of Health Labour and Welfare in 2006, has notable therapeutic effects on spasticity derived from any sort of central nervous disorder. More promotive enlightenment if ITB is indispensable for enhancement of its medical benefit in Japan.
Collapse
Affiliation(s)
- T Nakajima
- Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
46
|
Kitajima M, Satoh G, Marusasa T, Konishi N, Watanabe T, Ochiai T, Nishimura K, Futagawa S. [A case of gastric cancer with peritoneal dissemination-efficacy of combination therapy with S-1 and docetaxel]. Gan To Kagaku Ryoho 2009; 36:1545-1548. [PMID: 19755830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The efficiency of new anti-cancer drugs such as the S-1 system was demonstrated in a controlled study comparing treatment and non-treatment groups. We encountered a patient with gastric cancer demonstrating peritoneal dissemination, who was successfully treated by combination therapy using S-1 and docetaxel. A 62-year-old woman was admitted to the hospital due to appetite loss and nausea. Upper GI endoscopy demonstrated a type 3 gastric cancer extending from the upper to lower body of the stomach. In the pelvic cavity, an abdominal CT scan demonstrated massive ascites. An abnormally high CA72-4 (143.8 U/mL) level was detected in serum. Treatment with S-1 and docetaxel was started with the following regimen: daily oral administration of 80 mg/body S-1 for 14 days, followed by a 7-day rest and infusion of 40 mg/m2 docetaxel on day 1. After 4 courses, the sites of dissemination had disappeared, and the serum CA72-4 value returned to normal. The patient clinically achieved good QOL by this method, which was very effective for non-resected gastric cancer with peritoneal dissemination.
Collapse
Affiliation(s)
- Masayuki Kitajima
- Dept. of Surgery, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Ochiai T, Nagayama M, Nakamura T, Morrison T, Pilchak D, Kondo N, Hasegawa H, Song B, Serra R, Pacifici M, Koyama E. Roles of the primary cilium component Polaris in synchondrosis development. J Dent Res 2009; 88:545-50. [PMID: 19587160 DOI: 10.1177/0022034509337775] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Primary cilia regulate several developmental processes and mediate hedgehog signaling. To study their roles in cranial base development, we created conditional mouse mutants deficient in Polaris, a critical primary cilium component, in cartilage. Mutant post-natal cranial bases were deformed, and their synchondrosis growth plates were disorganized. Expression of Indian hedgehog, Patched-1, collagen X, and MMP-13 was reduced and accompanied by decreases in endochondral bone. Interestingly, there was excessive intramembranous ossification along the perichondrium, accompanied by excessive Patched-1 expression, suggesting that Ihh distribution was wider and responsible for such excessive response. Indeed, expression of heparan sulfate proteoglycans (HS-PGs), normally involved in restricting hedgehog distribution, was barely detectable in mutant synchondroses. Analyses of the data provides further evidence for the essential roles of primary cilia and hedgehog signaling in cranial base development and chondrocyte maturation, and point to a close interdependence between cilia and HS-PGs to delimit targets of hedgehog action in synchondroses.
Collapse
Affiliation(s)
- T Ochiai
- Department of Orthopaedic Surgery, Thomas Jefferson University College of Medicine, 1015 Walnut Street, Curtis Building, Room 501, Philadelphia, PA 19107, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakayama N, Mashiko S, Yamazaki R, Kaneko N, Futagawa S, Nagaoka I. Evaluation of the distinction between responder and non-responder in FOLFOX/FOLFIRI based on the alteration of serum iron level. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15110 Background: The alteration of serum-iron level during chemotherapy is already reported (Follezou, NEOPLASMA 1985). However, the correlation to prognosis has not been evaluated. The aim of this study was to evaluate the correlation between prognosis and serum-iron level in advanced / metastatic colorectal cancer (aCRC / mCRC) patients treated by FOLFOX / FOLFIRI. Methods: Serum-iron levels, hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were analyzed in 58 aCRC / mCRC patients received FOLFOX-4 / FOLFIRI therapy between April 2005 and September 2008. 26 patients received FOLFOX-4 / FOLFIRI therapy as the final chemotherapy died by the time of analysis. These patients were categorized into the high increase group and the low increase group using 200% increase as cut-off value and the prognosis was compared. Results: Mean serum-iron levels in immediately pre and post chemotherapy were 71.7±29.0μg/dl and 186.8±83.2μg/dl, respectively, and significant increase after chemotherapy was observed (p<0.001). This increase was transient and returns to pre chemotherapy level by the start of next course. This alteration was always observed on the chemotherapy. The median survival times from the initiation of FOLFOX-4 / FOLFIRI therapy for the high increase group (n: 5) and the low increase group (n: 21) were 487 and 182 days, respectively, and was significantly better in the high increase group (p=0.004). The alterations of hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were not observed. Conclusions: It is suggested that serum-iron increase is a biological response not attributed to leakage from erythrocyte and hepatocyte. Significantly better prognosis in high serum-iron group may suggest the usefulness of serum-iron level to distinguish responder and non-responder in FOLFOX-4/FOLFIRI therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Ochiai
- Tobu Chiiki Hospital, Tokyo, Japan; Juntendo University School of Medicine, Tokyo, Japan
| | - K. Nishimura
- Tobu Chiiki Hospital, Tokyo, Japan; Juntendo University School of Medicine, Tokyo, Japan
| | - T. Watanabe
- Tobu Chiiki Hospital, Tokyo, Japan; Juntendo University School of Medicine, Tokyo, Japan
| | - M. Kitajima
- Tobu Chiiki Hospital, Tokyo, Japan; Juntendo University School of Medicine, Tokyo, Japan
| | - N. Nakayama
- Tobu Chiiki Hospital, Tokyo, Japan; Juntendo University School of Medicine, Tokyo, Japan
| | - S. Mashiko
- Tobu Chiiki Hospital, Tokyo, Japan; Juntendo University School of Medicine, Tokyo, Japan
| | - R. Yamazaki
- Tobu Chiiki Hospital, Tokyo, Japan; Juntendo University School of Medicine, Tokyo, Japan
| | - N. Kaneko
- Tobu Chiiki Hospital, Tokyo, Japan; Juntendo University School of Medicine, Tokyo, Japan
| | - S. Futagawa
- Tobu Chiiki Hospital, Tokyo, Japan; Juntendo University School of Medicine, Tokyo, Japan
| | - I. Nagaoka
- Tobu Chiiki Hospital, Tokyo, Japan; Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
49
|
Kaihara S, Ushigome H, Sakai K, Yoshizawa A, Nobori S, Suzuki T, Okamoto M, Ochiai T, Yoshimura N. Preemptive living donor liver transplantation in glycogen storage disease Ia: case report. Transplant Proc 2008; 40:2815-7. [PMID: 18929868 DOI: 10.1016/j.transproceed.2008.07.026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
UNLABELLED Even with substantial progress in the management of patients with glycogen storage disease type Ia (GSD-Ia), hepatic and renal complications may still develop during long-term follow-up. Herein, we report a case of preemptive living donor liver transplantation in a patient with GSD-Ia. PATIENT The patient was a 5-year-old boy in whom GSD-Ia was diagnosed at age 10 months. Clinical symptoms included frequent hypoglycemic episodes, hyperlipidemia, hyperuricemia, and growth retardation, which were poorly controlled using conventional treatments. At age 5 years, frequent massive nasal bleeds developed, which led to severe anemia. The patient was brought to our institute for living donor liver transplantation (LDLT). Because GSD-Ia usually responds to dietary and medical treatments, we had a long discussion to determine whether preemptive LDLT was indicated. Transplantation was performed using the left lateral liver segment from the patients mother. The weight of his native liver was almost 2 kg. After reperfusion of the graft, the blood glucose concentration rapidly increased, and regular glucose was administered throughout the operation. The posttransplantation course was uneventful. The patient had no episodes of hypoglycemia with a regular diet. Total cholesterol, triglyceride, and uric acid concentrations also reverted to normal without medication. The patient had a few episodes of nasal bleeding after transplantation, which stopped spontaneously. He was discharged from our hospital with normal liver function. CONCLUSION Patients with GSD-Ia should be considered for preemptive LDLT to improve their quality of life when clinical symptoms do not respond to appropriate treatment.
Collapse
Affiliation(s)
- S Kaihara
- Department of Surgery, Kobe City General Hospital, Kobe, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Ushigome H, Sakai K, Suzuki T, Nobori S, Yoshizawa A, Ikoma H, Ochiai T, Kaihara S, Okamoto M, Sakamoto S, Yoshimura N. Biliary Anastomosis and Biliary Complications Following Living Donor Liver Transplantation. Transplant Proc 2008; 40:2537-8. [DOI: 10.1016/j.transproceed.2008.07.060] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|